Enobia Pharma

Enobia Pharma

Alexion Pharmaceuticals, Inc (NASDAQ: ALXN) | World Leader in Treatments for Patients with Devastating and Rare Diseases. Learn more

Launch date
Employees
Market cap
-
Enterprise valuation
€145—218m (Dealroom.co estimates Aug 2011.)
Montreal Quebec (HQ)
  • Edit
DateInvestorsAmountRound

$15.6m

Series A

$40.1m

Series B

$50.0m

Series C
N/A

$15.0m

Late VC
N/A

$40.0m

Late VC

N/A

Acquisition
Total Funding€146m

Recent News about Enobia Pharma

Edit
More about Enobia Pharmainfo icon
Edit

Enobia operates in the mental health and wellness sector, providing an extensive online therapy platform that specializes in Cognitive Behavioral Therapy (CBT). The company serves individuals seeking mental health support, including those dealing with conditions such as ADHD, hypophosphatasia, and Oppositional Defiant Disorder (ODD). Enobia's market includes both direct consumers and healthcare providers looking for effective, evidence-based therapeutic solutions. The business model is subscription-based, where clients pay for access to therapy sessions, personalized guidance from licensed therapists, and a variety of mental health resources. Revenue is generated through these subscriptions as well as potential partnerships with healthcare institutions. Enobia's unique selling proposition lies in its comprehensive, evidence-based CBT programs and the convenience of online access, making mental health support more accessible and affordable.

Keywords: Cognitive Behavioral Therapy, online therapy, mental health, ADHD, hypophosphatasia, ODD, personalized guidance, subscription-based, evidence-based, healthcare partnerships.

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.